Alnylam Receives Fast Track Designation for Vutrisiran for the Treatment of the Polyneuropathy of hATTR Amyloidosis

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 14, 2020-- Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials